---
document_datetime: 2023-09-21 19:01:46
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pumarix-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: pumarix-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.5994067
conversion_datetime: 2025-12-30 13:08:11.136733
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pumarix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                           |
|----------------------|------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0009            | Periodic Safety Update.                                                                        | 18/12/2013                                  | 28/02/2014                                     | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0009. |
| IG/0306              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 12/06/2013                                  | n/a                                            |                                  |                                                                                                                                   |
| IG/0297              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 19/04/2013                                  | n/a                                            |                                  |                                                                                                                                   |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IG/0265/G   | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                    | 28/01/2013   | n/a           | longer                           | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0004     | Increase in storage condition for reconstituted product and formatting of Product Information. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/08/2012   | 29/10/2012 no | SmPC, Annex II, Labelling and PL | The Product Information was updated to reflect an increase in the in-use storage temperature resulting in changes to the to recommend storage for up to 24 hours at up to 30ÂºC after mixing of the antigen and adjuvant components. In addition the Product Information was updated in line with the QRD template version 8.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| WS/0153     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC to include a warning on psychogenic syncope based on the available safety data. The PL was proposed to be updated in accordance. In addition, the company took the opportunity to update the list of local representatives in the PL of Pumarix, Ambirix, Pandemrix, Pandemic influenza vaccine (H5N1) (split Medicinal product | 17/11/2011   | 09/01/2012    | SmPC and PL                      | Based on a review of literature and a search in the global safety database performed by the MAH, the CHMP recommended including a wording on psychogenic syncope to the product information of the MAH injectable vaccines. The literature review showed an incidence peak occurred around the age of 15 years, with females having more than twice the incidence of males. The syncope reports with secondary injuries were reported most frequently in children and adolescents. Given that psychogenic syncope is not a true side effect, it was not considered appropriate to include syncope as an undesirable effect in section 4.8 of the SmPC. However, as such events can result in injury, and may not have occurred in the absence of the vaccination, the CHMP recommended |

<div style=\"page-break-after: always\"></div>

|         | virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals, Prepandrix and Fendrix. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            | authorised   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------|
| IG/0133 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                         | 22/11/2011 | n/a          |
| IG/0081 | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                               | 07/07/2011 | n/a longer   |

Medicinal product no longer authorised